Pieris and Servier, an independent international pharmaceutical company headquartered in France with annual sales of more than EUR4 billion, to jointly pursue several bispecific therapeutic programs including Pieris’ proprietary dual checkpoint inhibitor PRS-332 Alliance includes four additional bispecific programs and may be expanded to a total of eight immuno-oncology programs ; Pieris has option to co-develop and retain US rights for 4 of these programs, including PRS-332 Pieris to receive EUR30 million upfront, up to EUR324 million in success-based payments for PRS-332, up to EUR193 million in success-based payments for each of the other programs and up to double-digit royalties Pieris will host an investor conference call on Thursday, January 5, 2017 at 8:30 AM to discuss the collaboration : PIRS ) , a clinical-stage biotechnology company advancing novel biotherapeutics through its … (more)